** J.P. Morgan upgrades gene therapy maker bluebird bio BLUE.O to "neutral" from "underweight" rating, citing co's announcement that it would be taken private
** Brokerage expects co's privatization to take place within 1H25
** BLUE says it will be taken private by Carlyle CG.O and SK Capital Partners
** 1 of 8 brokerages rate BLUE stock "buy", 7 "hold"; their median PT is $10 - LSEG data
** As of last close, stock down ~51.1% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。